Bristol-Myers Squibb BMY Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Bristol-Myers Squibb’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bristol-Myers Squibb's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bristol-Myers Squibb's investing cash flow?
- Bristol-Myers Squibb (BMY) reported investing cash flow of -$131M in Q1 2026.
- How has Bristol-Myers Squibb's investing cash flow changed year-over-year?
- Bristol-Myers Squibb's investing cash flow increased by 73.7% year-over-year, from -$499M to -$131M.
- What is the long-term trend for Bristol-Myers Squibb's investing cash flow?
- Over 2 years (2023 to 2025), Bristol-Myers Squibb's investing cash flow has grown at a 34.2% compound annual growth rate (CAGR), from -$2.3B to -$4.13B.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.